Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Demographic and clinical characteristics of patients with systemic lupus erythematosus across five registries: the LupusNet federated data network.

Lupus science & medicine·2026
Same author

Self-reported depression on the Lupus Impact Tracker questionnaire (LIT) is associated with glucocorticoid use and fibromyalgia in systemic lupus erythematosus, according to RELESSER-PROS registry data.

BMC rheumatology·2026
Same author

Real-world experience of anifrolumab in 30 patients with refractory DM: a multicentre-multidisciplinary retrospective study.

Rheumatology (Oxford, England)·2025
Same author

Management and treatment of early rheumatoid arthritis, process and barriers among rheumatologists in Spain: a Delphi consensus.

BMC rheumatology·2025
Same author

Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data.

Lupus science & medicine·2025
Same author

Comorbidity clusters and their relationship with severity and outcomes of index diseases, in a large multicentre systemic lupus erythematosus cohort.

Lupus science & medicine·2025

Related Experiment Video

Updated: May 30, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

[New therapeutic targets].

Jaime Calvo Alén1

  • 1Sección de Reumatología. Hospital Sierrallana. Torrelavega. Cantabria. España.

Reumatologia Clinica
|July 29, 2011
PubMed
Summary
This summary is machine-generated.

Biologic therapies are advancing for rheumatic diseases like systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), and progressive systemic sclerosis (PSS). This review covers promising, near-future clinical applications of these novel treatments.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Related Experiment Videos

Last Updated: May 30, 2026

Protein Target Prediction and Validation of Small Molecule Compound
10:21

Protein Target Prediction and Validation of Small Molecule Compound

Published on: February 23, 2024

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability (DARTS) assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
11:44

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Context:

  • Biologic therapies have shown success in rheumatoid arthritis.
  • Their application is expanding to other rheumatic diseases including SLE, SS, and PSS.
  • This review focuses on biologic agents in advanced development stages.

Purpose:

  • To summarize emerging biologic therapies for SLE, SS, and PSS.
  • To highlight agents with potential for near-future clinical use.
  • To provide an overview of ongoing clinical trials for these conditions.

Summary:

  • Systemic Lupus Erythematosus (SLE) has numerous ongoing trials targeting B cells (rituximab, epratuzumab), lymphocyte proliferation (belimumab), and costimulation (abatacept).
  • Sjögren's Syndrome (SS) shows promise with rituximab and efalizumab.
  • Progressive Systemic Sclerosis (PSS) is exploring monoclonal antibodies against TGFβ and abatacept, though non-biologic agents like endothelin inhibitors are also advancing.

Impact:

  • This review offers insights into the future of biologic treatments for complex rheumatic diseases.
  • It identifies key therapeutic targets and agents under investigation.
  • Understanding these developments is crucial for clinicians and researchers in rheumatology.